MOE Key Laboratory of Gene Function and Regulation, State Key Laboratory for Biocontrol, School of Life Sciences, Sun Yat-Sen University, Guangzhou, 510275, China.
The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, 519000, China.
Sci China Life Sci. 2020 Apr;63(4):529-542. doi: 10.1007/s11427-019-9580-5. Epub 2019 Jun 24.
The roles of concealed microproteins encoded by long noncoding RNAs (lncRNAs) are gradually being exposed, but their functions in tumorigenesis are still largely unclear. Here, we identify and characterize a conserved 99-amino acid microprotein named KRASIM that is encoded by the putative lncRNA NCBP2-AS2. KRASIM is differentially expressed in normal hepatocytes and hepatocellular carcinoma (HCC) cells and can suppress HCC cell growth and proliferation. Mechanistically, KRASIM interacts and colocalizes with the KRAS protein in the cytoplasm of human HuH-7 hepatoma cells. More importantly, the overexpression of KRASIM decreases the KRAS protein level, leading to the inhibition of ERK signaling activity in HCC cells. These results demonstrate a novel microprotein repressor of the KRAS pathway for the first time and provide new insights into the regulatory mechanisms of oncogenic signaling and HCC therapy.
长链非编码 RNA(lncRNA)编码的隐匿性微蛋白的作用逐渐被揭示,但它们在肿瘤发生中的功能仍很大程度上不清楚。在这里,我们鉴定并表征了一个保守的 99 个氨基酸的微蛋白 KRASIM,它由假定的 lncRNA NCBP2-AS2 编码。KRASIM 在正常肝细胞和肝癌(HCC)细胞中表达差异,可抑制 HCC 细胞的生长和增殖。在机制上,KRASIM 在人 HuH-7 肝癌细胞的细胞质中与 KRAS 蛋白相互作用并共定位。更重要的是,KRASIM 的过表达降低了 KRAS 蛋白水平,导致 HCC 细胞中 ERK 信号活性的抑制。这些结果首次证明了 KRAS 通路的一种新型微蛋白抑制剂,并为致癌信号和 HCC 治疗的调控机制提供了新的见解。